Deborah J. Wexler

Jul 16, 2024 | dom-pubs.onlinelibrary.wiley.com | Karine Suissa |Sebastian Schneeweiss |Robert J Glynn |Deborah J. Wexler

Samy Suissa PhD Centre for Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital, Montreal, Quebec, Canada Department of Epidemiology, Biostatistics, and Occupational Health, McGill University, Montreal, Quebec, Canada Department of Medicine, McGill University, Montréal, Quebec, CanadaSearch for more papers by this author

Feb 9, 2023 | jamanetwork.com | Elvira D’Andrea |Deborah J. Wexler |Julie M. Paik |Ethan M. Alt

Key PointsQuestion  Does the effectiveness and safety of sodium-glucose cotransporter 2 inhibitors (SGLT2i) differ from that of dipeptidyl peptidase 4 inhibitors (DPP-4i) in patients with type 2 diabetes (T2D) overall and at varying baseline hemoglobin A1c (HbA1c) levels?